...
首页> 外文期刊>Vaccine >Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV)
【24h】

Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV)

机译:人二倍体细胞狂犬病疫苗(HDCV)预防接触后32年的抗体持久性

获取原文
获取原文并翻译 | 示例

摘要

In 1975-1976 forty-five persons severely bitten by rabid wolves and dogs in Iran were treated successfully against rabies with HDCV. In this study contact was made with 26 of 45 above persons, 32 years after their initial treatment and all had rabies neutralizing antibody ranging from 0.3 to 2.69IU/ml of serum. Of the 26 persons, 17 had received a booster dose of HDCV, 28 years ago and the remaining 9 persons, who had not received any booster since the initial treatment, were given one booster dose of HDCV. All 9 of these patients developed an anamnestic response after their booster inoculation. This study confirms the persistence of rabies neutralizing antibody in persons that received post-exposure vaccination with HDCV, 32 years previously. Furthermore, a single booster inoculation with HDCV resulted in anamnestic response in all individuals
机译:1975-1976年,在伊朗,有45名被狂犬病和狗严重咬伤的人用HDCV成功治疗了狂犬病。在这项研究中,与45位以上的人中的26位进行了接触,他们接受了最初的治疗32年后,所有人的狂犬病中和抗体的血清浓度范围为0.3至2.69IU / ml。在28年前的26人中,有17人接受了HDCV的加强剂量,而自最初治疗以来未接受过任何加强治疗的其余9人被给予了HDCV的加强剂量。在加强接种后,所有9名患者均出现了记忆消除反应。这项研究证实了32年前接受HDCV暴露后疫苗接种的人中狂犬病中和抗体的持久性。此外,单次加强接种HDCV会导致所有患者的记忆消除

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号